Literature DB >> 32002645

A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI.

Wentao Wang1, Dongsheng Gu2,3, Jingwei Wei2,3, Ying Ding1, Li Yang1, Kai Zhu4, Rongkui Luo5, Sheng-Xiang Rao1, Jie Tian6,7,8,9, Mengsu Zeng10.   

Abstract

OBJECTIVES: We aimed to develop a radiomics-based model derived from gadoxetic acid-enhanced MR images to preoperatively identify cytokeratin (CK) 19 status of hepatocellular carcinoma (HCC).
METHODS: A cohort of 227 patients with single HCC was classified into a training set (n = 159) and a time-independent validated set (n = 68). A total of 647 radiomic features were extracted from multi-sequence MR images. The least absolute shrinkage and selection operator regression and decision tree methods were utilized for feature selection and radiomics signature construction. A multivariable logistic regression model incorporating clinico-radiological features and the fusion radiomics signature was built for prediction of CK19 status by evaluating area under curve (AUC).
RESULTS: In the whole cohort, 57 patients were CK19 positive and 170 patients were CK19 negative. By combining 11 and 6 radiomic features extracted in arterial phase and hepatobiliary phase images, respectively, a fusion radiomics signature achieved AUCs of 0.951 and 0.822 in training and validation datasets. The final combined model integrated a-fetoprotein levels, arterial rim enhancement pattern, irregular tumor margin, and the fusion radiomics signature, with a sensitivity of 0.818 and specificity of 0.974 in the training cohort and that of 0.769 and 0.818 in the validated cohort. The nomogram based on the combined model showed satisfactory prediction performance in training (C-index 0.959) and validation (C-index 0.846) dataset.
CONCLUSIONS: The combined model based on a fusion radiomics signature derived from arterial and hepatobiliary phase images of gadoxetic acid-enhanced MRI can be a reliable biomarker for CK19 status of HCC. KEY POINTS: • Arterial rim enhancement pattern and irregular tumor margin on hepatobiliary phase on gadoxetic acid-enhanced MRI can be useful for evaluating CK19 status of HCC. • A radiomics-based model performed better than the clinico-radiological model both in training and validation datasets for predicting CK19 status of HCC. • The nomogram based on the fusion radiomics signature can be easily used for CK19 stratification of HCC.

Entities:  

Keywords:  Cytokeratin 19; Diagnosis; Hepatocellular carcinoma

Mesh:

Substances:

Year:  2020        PMID: 32002645     DOI: 10.1007/s00330-019-06585-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  14 in total

1.  Preoperative radiomics model using gadobenate dimeglumine-enhanced magnetic resonance imaging for predicting β-catenin mutation in patients with hepatocellular carcinoma: A retrospective study.

Authors:  Fengxia Zeng; Hui Dai; Xu Li; Le Guo; Ningyang Jia; Jun Yang; Danping Huang; Hui Zeng; Weiguo Chen; Ling Zhang; Genggeng Qin
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

2.  Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy.

Authors:  Shang-Dong Qin; Jie Zhang; Ya-Peng Qi; Jian-Hong Zhong; Bang-De Xiang
Journal:  World J Surg Oncol       Date:  2022-06-21       Impact factor: 3.253

Review 3.  AI in spotting high-risk characteristics of medical imaging and molecular pathology.

Authors:  Chong Zhang; Jionghui Gu; Yangyang Zhu; Zheling Meng; Tong Tong; Dongyang Li; Zhenyu Liu; Yang Du; Kun Wang; Jie Tian
Journal:  Precis Clin Med       Date:  2021-12-04

4.  Texture Analysis Based on Gd-EOB-DTPA-Enhanced MRI for Identifying Vessels Encapsulating Tumor Clusters (VETC)-Positive Hepatocellular Carcinoma.

Authors:  Yanfen Fan; Yixing Yu; Ximing Wang; Mengjie Hu; Mingzhan Du; Lingchuan Guo; Shifang Sun; Chunhong Hu
Journal:  J Hepatocell Carcinoma       Date:  2021-05-05

5.  Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm.

Authors:  Huan-Huan Chong; Li Yang; Ruo-Fan Sheng; Yang-Li Yu; Di-Jia Wu; Sheng-Xiang Rao; Chun Yang; Meng-Su Zeng
Journal:  Eur Radiol       Date:  2021-01-14       Impact factor: 5.315

6.  Multi-phase contrast-enhanced magnetic resonance image-based radiomics-combined machine learning reveals microscopic ultra-early hepatocellular carcinoma lesions.

Authors:  Kui Sun; Liting Shi; Jianfeng Qiu; Yuteng Pan; Ximing Wang; Haiyan Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-01       Impact factor: 10.057

Review 7.  Progress of MRI Radiomics in Hepatocellular Carcinoma.

Authors:  Xue-Qin Gong; Yun-Yun Tao; Yao-Kun Wu; Ning Liu; Xi Yu; Ran Wang; Jing Zheng; Nian Liu; Xiao-Hua Huang; Jing-Dong Li; Gang Yang; Xiao-Qin Wei; Lin Yang; Xiao-Ming Zhang
Journal:  Front Oncol       Date:  2021-09-20       Impact factor: 6.244

8.  Positron Emission Tomography/Magnetic Resonance Imaging Radiomics in Predicting Lung Adenocarcinoma and Squamous Cell Carcinoma.

Authors:  Xin Tang; Jiangtao Liang; Bolin Xiang; Changfeng Yuan; Luoyu Wang; Bin Zhu; Xiuhong Ge; Min Fang; Zhongxiang Ding
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

9.  Peritumoral Dilation Radiomics of Gadoxetate Disodium-Enhanced MRI Excellently Predicts Early Recurrence of Hepatocellular Carcinoma without Macrovascular Invasion After Hepatectomy.

Authors:  Huanhuan Chong; Yuda Gong; Xianpan Pan; Aie Liu; Lei Chen; Chun Yang; Mengsu Zeng
Journal:  J Hepatocell Carcinoma       Date:  2021-06-09

10.  Preoperative Prediction of Cytokeratin 19 Expression for Hepatocellular Carcinoma with Deep Learning Radiomics Based on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging.

Authors:  Yuying Chen; Jia Chen; Yu Zhang; Zhi Lin; Meng Wang; Lifei Huang; Mengqi Huang; Mimi Tang; Xiaoqi Zhou; Zhenpeng Peng; Bingsheng Huang; Shi-Ting Feng
Journal:  J Hepatocell Carcinoma       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.